Journal article
Neurobehavioral outcomes 11 years after neonatal caffeine therapy for apnea of prematurity
IM Mürner-Lavanchy, LW Doyle, B Schmidt, RS Roberts, EV Asztalos, L Costantini, PG Davis, D Dewey, J D'Ilario, RE Grunau, D Moddemann, H Nelson, A Ohlsson, A Solimano, W Tin, PJ Anderson, J Dix, BA Adams, E Warriner, C Callanan Show all
Pediatrics | Published : 2018
Abstract
BACKGROUND AND OBJECTIVES: Caffeine is effective in the treatment of apnea of prematurity. Although caffeine therapy has a benefit on gross motor skills in school-aged children, effects on neurobehavioral outcomes are not fully understood. We aimed to investigate effects of neonatal caffeine therapy in very low birth weight (500-1250 g) infants on neurobehavioral outcomes in 11-year-old participants of the Caffeine for Apnea of Prematurity trial. METHODS: Thirteen academic hospitals in Canada, Australia, Great Britain, and Sweden participated in this part of the 11-year follow-up of the double-blind, randomized, placebocontrolled trial. Measures of general intelligence, attention, executive ..
View full abstractGrants
Awarded by Canadian Institutes of Health Research
Funding Acknowledgements
Supported by the Canadian Institutes of Health Research (MOP 102601).